Hepatitis Monthly

Published by: Kowsar

Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience

Zaigham Abbas 1 , 2 , * , Muhammad Saad 1 , Ramlah Nadeem 2 , Fahad Jawed 2 and Minaam Abbas 2
Authors Information
1 Department of Gastroenterology, Dr. Ziauddin University, Karachi 75500, Pakistan
2 Department of Medicine, Orthopedic and Medical Institute, Karachi 74400, Pakistan
Article information
  • Hepatitis Monthly: April 2017, 17 (4); e12297
  • Published Online: April 12, 2017
  • Article Type: Research Article
  • Received: January 28, 2017
  • Revised: February 26, 2017
  • Accepted: March 14, 2017
  • DOI: 10.5812/hepatmon.45525

To Cite: Abbas Z, Saad M, Nadeem R, Jawed F, Abbas M. et al. Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience, Hepat Mon. 2017 ;17(4):e12297. doi: 10.5812/hepatmon.45525.

Abstract
Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Introduction
2. Objectives
3. Methods
4. Results
5. Discussion
Footnote
References
  • 1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl)-57[DOI][PubMed]
  • 2. Attaullah S, Khan S, Ali I. Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J. 2011; 8: 433[DOI][PubMed]
  • 3. Aghemo A, Dore GJ, Hatzakis A, Wedemeyer H, Razavi H. Estimating HCV disease burden - volume 3 (editorial). J Viral Hepat. 2015; 22 Suppl 4: 1-3[DOI][PubMed]
  • 4. Aasld Idsa Hcv Guidance Panel . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3): 932-54[DOI][PubMed]
  • 5. Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int. 2016; 10(6): 861-70[DOI][PubMed]
  • 6. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370(21): 1993-2001[DOI][PubMed]
  • 7. Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015; 149(6): 1462-70[DOI][PubMed]
  • 8. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20): 1878-87[DOI][PubMed]
  • 9. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20): 1867-77[DOI][PubMed]
  • 10. Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. J Gastroenterol Hepatol. 2017; 32(4): 859-63[DOI][PubMed]
  • 11. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, et al. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016; 63(8): 1042-8[DOI][PubMed]
  • 12. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61(4): 1127-35[DOI][PubMed]
  • 13. Poordad F, Lawitz E, Gutierrez JA, Evans B, Howe A, Feng HP, et al. O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks. J Hepatol. 2015; 62-3[DOI]
  • 14. Alfaleh FZ, Nugrahini N, Maticic M, Tolmane I, Alzaabi M, Hajarizadeh B, et al. Strategies to manage hepatitis C virus infection disease burden - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 42-65[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader